Business Context and Reporting Period
This Form 8-K filing by Magenta Therapeutics, Inc. (not Dianthus Therapeutics, Inc., as noted in the metadata) reports on the Annual Meeting of Stockholders held on June 5, 2020. The company is incorporated in Delaware and trades on the Nasdaq Global Market under the symbol MGTA. The filing details the voting results for director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused solely on corporate governance events and does not contain financial performance data.
Material Changes and Voting Results
The primary material event reported is the outcome of two stockholder proposals:
- Proposal 1: Election of Class II Directors
- Four directors were elected for a three-year term ending in 2023: Jeffrey Albers, Michael W. Bonney, Anne McGeorge, and David T. Scadden, M.D.
- Voting Summary:
- Jeffrey Albers: 23,332,681 For; 4,526,576 Withheld.
- Michael W. Bonney: 22,928,122 For; 4,931,135 Withheld.
- Anne McGeorge: 23,342,475 For; 4,516,782 Withheld.
- David T. Scadden, M.D.: 21,418,182 For; 6,441,075 Withheld.
- All nominees received significant broker non-votes (8,391,091 each).
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Voting Summary: 36,121,035 For; 83,461 Against; 45,852 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document strictly reports the procedural results of the Annual Meeting.
Key Facts for Investor Verification
- Verify the company name discrepancy: The metadata lists "Dianthus Therapeutics, Inc.," but the filing is for "Magenta Therapeutics, Inc."
- Confirm the tenure of the newly elected Class II directors, which extends until the 2023 annual meeting.
- Note the significant number of broker non-votes (approx. 8.4 million) for the director elections, indicating shares held by brokers that were not voted on these matters.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 24, 2020) for detailed background on the director nominees and auditor selection.